What does Avidity Biosciences, Inc. do?

Jun 22 2025 06:22 PM IST
share
Share Via
Avidity Biosciences, Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOC) for serious diseases, with a market cap of approximately $3.54 billion. As of March 2025, it reported net sales of $2 million and a net loss of $116 million.
Overview:
Avidity Biosciences, Inc. is a biopharmaceutical company focused on developing oligonucleotide-based therapies known as Antibody Oligonucleotide Conjugates (AOC) to treat serious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.

Financial Snapshot:
Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025)
Most recent Net Profit: -116 Million (Quarterly Results - Mar 2025)
Market cap: USD 3,539.01 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 0.00%
Debt Equity: -1.04
Return on Equity: -27.79%
Price to Book: 2.66

Contact Details:
Address: 10975 N. TORREY PINES RD., #150, LA JOLLA CA : 92037
Tel: 1 858 4017900
Website: http://www.aviditybiosciences.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News